Printable: How important is the new IMWG response criteria, which includes the use of minimal residual disease testing?

How important is the new IMWG response criteria, which includes the use of minimal residual disease testing? (https://www.myeloma.org/videos/how-important-new-imwg-response-criteria-which-includes-use-minimal-residual-disease-testing)

In this week’s video, Dr. Brian G.M. Durie explains why MRD testing is important for assessing the results of clinical trials, but is not yet ready for the clinic.

BOTTOM LINE:
In clinical trials, the new criteria are essential to assess new drug combination therapies.

Author

Dr. Brian GM Durie (https://www.myeloma.org/Brian-Durie-md)

Video

Series

Ask Dr. Durie (https://www.myeloma.org/taxonomy/term/19)

Old Id

599

Ask a Question

Please note that Ask Dr. Durie has been discontinued, and it was designed to address myeloma questions of the broadest possible audience interest. If you have a question of a personal nature, please contact our InfoLine Coordinators at 800.452.2873 or [email protected] (mailto:[email protected]) (Please do not send email attachments or lab reports.).

Image of Dr. Brian G.M. Durie Dr. Brian G.M. Durie (1942-2025) was the co-founder of the IMF. He was a Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels.